Cargando…

Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update

Colorectal cancer (CRC) remains as one of the most common cause of worldwide cancer morbidity and mortality. Improvements in surgical modalities and adjuvant chemotherapy have increased the cure rates in early stage disease, but a significant portion of the patients will develop recurrence or advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ab Mutalib, Nurul-Syakima, Md Yusof, Najwa F., Abdul, Shafina-Nadiawati, Jamal, Rahman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644034/
https://www.ncbi.nlm.nih.gov/pubmed/29075194
http://dx.doi.org/10.3389/fphar.2017.00736
_version_ 1783271649427062784
author Ab Mutalib, Nurul-Syakima
Md Yusof, Najwa F.
Abdul, Shafina-Nadiawati
Jamal, Rahman
author_facet Ab Mutalib, Nurul-Syakima
Md Yusof, Najwa F.
Abdul, Shafina-Nadiawati
Jamal, Rahman
author_sort Ab Mutalib, Nurul-Syakima
collection PubMed
description Colorectal cancer (CRC) remains as one of the most common cause of worldwide cancer morbidity and mortality. Improvements in surgical modalities and adjuvant chemotherapy have increased the cure rates in early stage disease, but a significant portion of the patients will develop recurrence or advanced disease. The efficacy of chemotherapy of recurrence and advanced CRC has improved significantly over the last decade. Previously, the historical drug 5-fluorouracil was used as single chemotherapeutic agent. Now with the addition of other drugs such as capecitabine, irinotecan, oxaliplatin, bevacizumab, cetuximab, panitumumab, vemurafenib, and dabrafenib, the median survival of patients with advanced CRC has significantly improved from less than a year to the current standard of almost 2 years. However, the side effects of systemic therapy such as toxicity may cause fatal complications and have a major consequences on the patients’ quality of life. Hence, there is an urgent need for key biomarkers which will enable the selection of optimal drug singly or in combination for an individual patient. The application of personalized therapy based on DNA testing could aid the clinicians in providing the most effective chemotherapy agents and dose modifications for each patient. Yet, some of the current findings are controversial and the evidences are conflicting. This review aims at summarizing the current state of knowledge about germline pharmacogenomics DNA variants that are currently used to guide therapeutic decisions and variants that have the potential to be clinically useful in the future. In addition, current updates on germline variants conferring treatment sensitivity, drug resistance to existing chemotherapy agents and variants affecting prognosis and survival will also be emphasized. Different alteration in the same gene might confer resistance or enhanced sensitivity; and while most of other published reviews generally stated only the gene name and codon location, we will specifically discuss the exact variants to offer more accurate information in this mini review.
format Online
Article
Text
id pubmed-5644034
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-56440342017-10-26 Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update Ab Mutalib, Nurul-Syakima Md Yusof, Najwa F. Abdul, Shafina-Nadiawati Jamal, Rahman Front Pharmacol Pharmacology Colorectal cancer (CRC) remains as one of the most common cause of worldwide cancer morbidity and mortality. Improvements in surgical modalities and adjuvant chemotherapy have increased the cure rates in early stage disease, but a significant portion of the patients will develop recurrence or advanced disease. The efficacy of chemotherapy of recurrence and advanced CRC has improved significantly over the last decade. Previously, the historical drug 5-fluorouracil was used as single chemotherapeutic agent. Now with the addition of other drugs such as capecitabine, irinotecan, oxaliplatin, bevacizumab, cetuximab, panitumumab, vemurafenib, and dabrafenib, the median survival of patients with advanced CRC has significantly improved from less than a year to the current standard of almost 2 years. However, the side effects of systemic therapy such as toxicity may cause fatal complications and have a major consequences on the patients’ quality of life. Hence, there is an urgent need for key biomarkers which will enable the selection of optimal drug singly or in combination for an individual patient. The application of personalized therapy based on DNA testing could aid the clinicians in providing the most effective chemotherapy agents and dose modifications for each patient. Yet, some of the current findings are controversial and the evidences are conflicting. This review aims at summarizing the current state of knowledge about germline pharmacogenomics DNA variants that are currently used to guide therapeutic decisions and variants that have the potential to be clinically useful in the future. In addition, current updates on germline variants conferring treatment sensitivity, drug resistance to existing chemotherapy agents and variants affecting prognosis and survival will also be emphasized. Different alteration in the same gene might confer resistance or enhanced sensitivity; and while most of other published reviews generally stated only the gene name and codon location, we will specifically discuss the exact variants to offer more accurate information in this mini review. Frontiers Media S.A. 2017-10-12 /pmc/articles/PMC5644034/ /pubmed/29075194 http://dx.doi.org/10.3389/fphar.2017.00736 Text en Copyright © 2017 Ab Mutalib, Md Yusof, Abdul and Jamal. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ab Mutalib, Nurul-Syakima
Md Yusof, Najwa F.
Abdul, Shafina-Nadiawati
Jamal, Rahman
Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update
title Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update
title_full Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update
title_fullStr Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update
title_full_unstemmed Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update
title_short Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update
title_sort pharmacogenomics dna biomarkers in colorectal cancer: current update
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644034/
https://www.ncbi.nlm.nih.gov/pubmed/29075194
http://dx.doi.org/10.3389/fphar.2017.00736
work_keys_str_mv AT abmutalibnurulsyakima pharmacogenomicsdnabiomarkersincolorectalcancercurrentupdate
AT mdyusofnajwaf pharmacogenomicsdnabiomarkersincolorectalcancercurrentupdate
AT abdulshafinanadiawati pharmacogenomicsdnabiomarkersincolorectalcancercurrentupdate
AT jamalrahman pharmacogenomicsdnabiomarkersincolorectalcancercurrentupdate